Racura Appoints Contract Research Organisation for Lung Cancer Trial

MT Newswires Live

Dec 24, 2025

Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.

The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.

The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593449591"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593449591\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593449591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593449591","market":"nz","top_or_hot":-1,"title":"Racura Appoints Contract Research Organisation for Lung Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.</p><p>The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.</p><p>The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Appoints Contract Research Organisation for Lung Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Appoints Contract Research Organisation for Lung Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-24 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.</p><p>The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.</p><p>The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593449591","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593449591","pubTimestamp":1766532203,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Racura任命肺癌试验合同研究组织","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}